University of Dundee

Latest News

April 2019

  • Professor Kim Dale
    19 Apr 2019

    Latest research from Professor Kim Dale and collaborators has uncovered further knowledge into the developmental segmentation process which may also impact on our understanding of diseases such as cancer. This research was published this week in EMBO Reports.

  • Professor Doreen Cantrell and Professor Grahame Hardie
    17 Apr 2019

    Researchers from the Division of Cell Signalling and Immunology in the School have shown that a drug previously used to treat Type 2 diabetes could potentially be used to protect against cancer. A study carried out by Professors Grahame Hardie and Doreen Cantrell has shown that the drug phenformin protects mice against a type of cancer called T-cell lymphoma. It does this by switching on the protein AMPK, which was first defined by Professor Hardie in the 1980s. Subsequent research at Dundee showed a link between AMPK and cancer.

  • Photo (from left): Shanade Dunn and Olivia Lombardi
    17 Apr 2019

    One of the most prevalent cancer-causing genes or “oncogenes” is called PI3KCA.  Damaging changes or “mutations” in this oncogene are found in many cancers including cancers of the breast, colon, brain, liver, stomach and lung.   Understanding how cancer-causing genes such as PIK3CA change the behaviour of our cells is key to developing new therapies for cancer patients. 

  • Overview of the HaloPROTAC method to induce post–translational knockdown or endogenous proteins
    15 Apr 2019

    Hannah Tovell an Alessi lab PhD student working closely with the Ciulli lab has published an improved HaloPROTAC method to induce post–translational knockdown of endogenous proteins.  This approach makes use of CRISPR/Cas9 genome editing technology to introduce a Halo tag onto the N or C terminus of any desired target protein that can then be targeted for degradation by a HaloPROTAC probe (see Figure). 

  • 11 Apr 2019

    Professor Kate Storey has been awarded the Waddington Medal by the British Society for Developmental Biology. The Waddington Medal is the only national award in Developmental Biology. It honours outstanding research performance as well as services to the subject community. The medal is awarded annually at the BSDB Spring Meeting, where the recipient presents the Waddington Medal Lecture. Professor Storey is Head of the Division of Cell & Developmental Biology and Chair of Neural Development in the School of Life Sciences at Dundee.

  • 05 Apr 2019

    Following the destruction of lab space by the fire at Biomedical Sciences Building at the University of St Andrews, 8 researchers from the groups of David Hughes and Rick Randall will be accommodated within Gene Regulation and Expression in the School. 

  • Dr Kasper Rasmussen
    05 Apr 2019

    In a new study, researchers from the University of Copenhagen and EMBL in Heidelberg have learned how a specific genetic mutation affects the maturation of blood cells in mouse models. Leukaemia patients often have a mutation in this gene, often seen before the disease sets in. The researchers are working on a strategy for treating the mutation.

March 2019

  • Professor Alessio Ciulli
    27 Mar 2019

    In an article in the journal Nature, Megan Scudellari reflects on the short history of PROTACs -  a new type of drug design that is galvanising the Pharmaceutical industry, with the first PROTAC drug from Arvinas about to enter phase-1 clinical trials.

  • Poster Prize Winners
    22 Mar 2019

    Last week, the School’s Annual Research Symposium was held at Crieff Hydro. The programme of talks and poster presentations covered the diverse research taking place in the School. Newly appointed Principal Investigators and Professors gave talks alongside more junior members of the School, who spoke as part of the SLS showcase sessions.

  • Professor Andrew Hopkins
    21 Mar 2019

    Exscientia, a world leader in artificial intelligence (“AI”) driven drug discovery and a spinout company of the University of Dundee announced today that it has entered a three-year AI drug discovery partnership with leading biopharma company Celgene, including an initial $25 million upfront payment and eligibility to receive substantial milestones based on the clinical, regulatory and commercial success of the program.

Pages